# A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours

> **NCT03082053** · PHASE1 · COMPLETED · sponsor: **ASLAN Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Advanced or Metastatic Biliary Tract Cancer
- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** varlitinib
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT03082053
- **Lead sponsor:** ASLAN Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2017-12-07
- **Final completion:** 2018-06-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082053, "A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03082053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*